Retatrutide Once-Weekly Schedule: What Trials Studied
Weekly administration is a feature of retatrutide research, not an approved treatment schedule available through FormBlends.
FormBlends Editorial Research · Updated 2026-09-27
What was studied
The 2023 phase 2 obesity trial assigned 338 adults to retatrutide groups or placebo. Administration was once weekly during the 48-week study. The protocol defined the intervention, participant selection, monitoring and outcomes. Those controls are part of the evidence, not optional details that can be removed from a published schedule.
Starting strategies were not uniform
The study included more than one starting-dose strategy and several target-dose groups. It is incorrect to describe one schedule as the starting regimen for every participant. Trial groups are experimental comparisons, not a dose-selection menu for readers.
What remains unsettled
The trial does not establish a routine consumer schedule, how to manage missed doses, indefinite maintenance, or how to switch from another medication. It also does not establish long-term safety merely because study participants received medical oversight. Adverse events and discontinuations remain essential to interpreting outcomes.
FormBlends and clinical access
Retatrutide is not FDA-approved, and FDA states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell it. Earlier language suggesting routine retatrutide care through FormBlends should not be treated as an available service. Questions about participation or protocol instructions belong with the relevant study team.